| Company Name: |
BePharm Ltd |
| Tel: |
400-685-9117 |
| Email: |
market@bepharm.com |
|
| | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate Basic information |
| Product Name: | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate | | Synonyms: | tert-butyl 2-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]acetate;tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate;tert-butyl [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]acetate;tert-butyl 2-[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetate;1H-Pyrazole-1-acetic acid, 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-, 1,1-dimethylethyl ester;Oxirane, 2-[9-(phenylMethoxy)ethyl]-;2-methylthiazole-11-carboxylic acid;1-[2-(tert-Butoxy)-2-oxoethyl]-1H-pyrazole-4-boronic Acid Pinacol Ester | | CAS: | 1006875-83-7 | | MF: | C15H25BN2O4 | | MW: | 308.18 | | EINECS: | | | Product Categories: | | | Mol File: | 1006875-83-7.mol |  |
| | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate Chemical Properties |
| Boiling point | 407.4±25.0 °C(Predicted) | | density | 1.08±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | pka | 1.45±0.10(Predicted) | | Appearance | White to off-white Solid |
| | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate Usage And Synthesis |
| Uses | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate is used as a reactant in the preparation of imidazotriazines and imidazopyrimidines as kinase inhibitors. | | Synthesis | Using 4-pyrazoleboronic acid pinacol ester (2.0 g, 10.31 mmol) and tert-butyl bromoacetate (2.212 g, 11.34 mmol) as the raw material, the mixture was reacted with potassium carbonate (1.709 g, 12.37 mmol) in acetone (20 mL) for 13 h at 65 °C with stirring under nitrogen protection. Upon completion of the reaction, the reaction mixture was poured into ice water (20 mL) and extracted with ethyl acetate (50 mL × 2). The organic phases were combined, washed with saturated brine, dried over anhydrous magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate = 5/1) to afford the target compound tert-butyl 2-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate (3 g, 8.76 mmol, 85% yield) as an oil. lC-MS (Method C): m/z 309.2 ([M+H]+), retention time: 1.946 min; 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.75 (s, 1H), 4.82 (s, 2H), 1.47 (s, 9H), 1.28 (s, 12H). | | References | [1] Patent: WO2016/123796, 2016, A1. Location in patent: Page/Page column 49; 50
[2] Patent: US2008/39457, 2008, A1. Location in patent: Page/Page column 36
[3] Patent: US2013/59835, 2013, A1. Location in patent: Paragraph 1146
[4] Patent: US2014/249132, 2014, A1. Location in patent: Paragraph 0424
[5] Patent: US2010/240634, 2010, A1. Location in patent: Page/Page column 57-58 |
| | tert-Butyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)acetate Preparation Products And Raw materials |
|